Anti-C-met antibody and methods of use thereof
Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc.
1. An isolated monoclonal antibody that binds to human c-Met, comprising:
a heavy chain variable region wherein the variable region comprises as a CDR1 the sequence of SEQ ID NO:10; as a CDR2 the sequence of SEQ ID NO:12, and as a CDR3 the sequence of SEQ ID NO:22; and
a light chain variable region wherein the variable region comprises as a CDR1 the sequence of SEQ ID NO:31, as a CDR2 the sequence of SEQ ID NO:33, and as a CDR3 the sequence of SEQ ID NO:43.
2. The isolated monoclonal antibody of claim 1 , wherein said antibody comprises a) a full length VH of clone 1, comprising SEQ ID NO:9 joined to SEQ ID NO:10 joined to SEQ ID NO:11 joined to SEQ ID NO:12 joined to SEQ ID NO:21 joined to SEQ ID NO:22 joined to SEQ ID NO:23; and b) a full length VL of clone 1 comprising SEQ ID NO:30 joined to SEQ ID NO:31 joined to SEQ ID NO:32 joined to SEQ ID NO:33 joined to SEQ ID NO:42 joined to SEQ ID NO:43 joined to SEQ ID NO:44.
3. An isolated monoclonal antibody that binds to human c-Met comprising:
a heavy chain variable region wherein the variable region comprises as a CDR1 the sequence of SEQ ID NO:14; as a CDR2 the sequence of SEQ ID NO:16, and as a CDR3 the sequence of SEQ ID NO:25; and
a light chain variable region wherein the variable region comprises as a CDR1 the sequence of SEQ ID NO:35; as a CDR2 the sequence of SEQ ID NO:37, and as a CDR3 the sequence of SEQ ID NO:46.
4. The isolated monoclonal antibody of claim 3 , wherein said antibody comprises a) a full length VH of clone 20 comprising SEQ ID NO:13 joined to SEQ ID NO:14 joined to SEQ ID NO:15 joined to SEQ ID NO:16 joined to SEQ ID NO:24 joined to SEQ ID NO:25 joined to SEQ ID NO:26; and b) a full length VL of clone 20 comprising SEQ ID NO:34 joined to SEQ ID NO:35 joined to SEQ ID NO:36 joined to SEQ ID NO:37 joined to SEQ ID NO:45 joined to SEQ ID NO:46 joined to SEQ ID NO:47.
5. The isolated monoclonal antibody of claim 3 that, when bound to c-Met on the surface of a living mammalian cell, is endocytosed by the cell.
6. The isolated monoclonal antibody of claim 3 , wherein said anybody is a single chain Fv (scFv), IgG, Fab, (Fab′)2, or (scFv′)2.
7. The isolated monoclonal antibody of claim 3 , wherein said antibody is labeled.
8. The isolated monoclonal antibody of claim 3 , wherein said antibody is conjugated to an anti-cancer agent.
9. A lipidic nanoparticle comprising a surface and an interior space, said interior space comprising an anti-cancer agent, wherein an isolated monoclonal antibody of claim 3 is attached to the surface of said lipidic nanoparticle.
10. The lipidic nanoparticle of claim 9 , wherein when the lipidic nanoparticle is contacted with a cell expressing cell surface c-Met, said antibody binds to the cell surface c-Met and the lipidic nanoparticle is endocytosed.
11. A composition comprising:
a pharmaceutically acceptable carrier; and
an isolated monoclonal antibody of claim 3 .
12. The composition of claim 11 , wherein said composition is formulated for parenteral administration.
13. The composition of claim 11 , wherein said composition is formulated for intravenous, intrathecal, or intraventricular administration.
14. A kit comprising a composition of claim 11 .
15. An isolated monoclonal antibody that binds to human c-Met comprising:
a heavy chain variable region wherein the variable region comprises as a CDR1 the sequence of SEQ ID NO:18; as a CDR2 the sequence of SEQ ID NO:20, and as a CDR3 the sequence of SEQ ID NO:28;
and a light chain variable region wherein the variable region comprises as a CDR1 the sequence of SEQ ID NO:39; as a CDR2 the sequence of SEQ ID NO:41, and as a CDR3 the sequence of SEQ ID NO:49.
16. The isolated monoclonal antibody of claim 15 , wherein said antibody comprises: a) a full length VH of clone 21 comprising SEQ ID NO:17 joined to SEQ ID NO:18 joined to SEQ ID NO:19 joined to SEQ ID NO:20 joined to SEQ ID NO:27 joined to SEQ ID NO:28 joined to SEQ ID NO:29; and b) a full length VL of clone 21 comprising SEQ ID NO:38 joined to SEQ ID NO:39 joined to SEQ ID NO:40 joined to SEQ ID NO:41 joined to SEQ ID NO:48 joined to SEQ ID NO:49 joined to SEQ ID NO:50.